DocMorris Increases 2026 Revenue Forecast Amid Strong Rx Growth

DocMorris AG announced an upward revision of its full-year revenue forecast to around 15%, up from the previous 12.5-15% projection. This adjustment follows significant growth in its prescription medicines segment, which saw an increase of over 90% in October. For the full year, the company anticipates a 60% rise in Rx growth. Other annual and medium-term targets remain unchanged.

The company also highlighted its strategic expansion through the acquisition of Medi24, a Swiss telemedicine provider. This move aims to bolster its Digital Services business, with anticipated contributions to EBITDA expected as early as 2027. The acquisition complements DocMorris’ established TeleClinic operations, enhancing its telemedicine offerings outside Germany.

These developments were discussed during the Capital Markets Day held in Heerlen/Aachen, where executives shared insights into strategic plans and operational progress. Participants were given a tour of DocMorris’ advanced logistics facility in Heerlen.